congresses-banner

The content contained is subject

PublicationView

Poster
T-DXd
ESMO Asia 2023 | December 1-3, 2023
Gastric Cancer
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Akira Ooki
Mini-Oral
Dato-DXd
ESMO Asia 2023 | December 1-3, 2023
Lung Cancer
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01
Myung-Ju Ahn
Mini-Oral
T-DXd
ESMO Asia 2023 | December 1-3, 2023
Other/Multi
Trastuzumab deruxtecan for pretreated patients with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 study
Do-Youn Oh
Mini-Oral
T-DXd
ESMO Asia 2023 | December 1-3, 2023
Lung Cancer
Trastuzumab deruxtecan in Asian patients with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant metastatic non-small cell lung cancer: Subgroup analysis of DESTINY-Lung02
Koichi Goto
Poster
T-DXd
ESMO Asia 2023 | December 1-3, 2023
Gastric Cancer
Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive locally advanced/metastatic gastric cancer or gastroesophageal junction adenocarcinoma: Primary efficacy and safety from the phase 2 single-arm DESTINY-Gastric06 trial
Lin Shen
Poster
Dato-DXd
ESMO Asia 2023 | December 1-3, 2023
Lung Cancer
TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations
Myung-Ju Ahn
Mini-Oral
Dato-DXd
ESMO Asia 2023 | December 1-3, 2023
Lung Cancer
TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer with actionable genomic alterations
Satoru Kitazono

footer